PSC
PCRX icon

Piper Sandler & Co’s Pacira BioSciences PCRX Stock Holding History

Piper Sandler & Co’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-100
Closed -$9K – 157
2014
Q2 		$9K Buy
+100
New +$7.62K 0.01% 111

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Piper Sandler & Co's PCRX Position: Q3 2014 in Review

Piper Sandler & Co sold out of Pacira BioSciences (PCRX) in Q3 2014, closing a stake of 100 shares — an estimated $9K sold.

Piper Sandler & Co first reported a position in PCRX in Q2 2014 and held it in 1 quarter. The position peaked at $9K in Q2 2014. 208 funds tracked by Wall St. Rank hold PCRX as of Q3 2014.

  • Piper Sandler & Co reported no remaining Pacira BioSciences position as of Q3 2014 after selling out during the quarter.
  • Piper Sandler & Co sold 100 Pacira BioSciences shares in Q3 2014, an estimated $9K.
  • Piper Sandler & Co first reported a position in Pacira BioSciences in Q2 2014 and held it in 1 quarter.
  • Piper Sandler & Co's Pacira BioSciences position peaked at $9K in Q2 2014.
  • 208 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2014.

Based on Piper Sandler & Co's 13F filing for Q3 2014, filed 14 Nov 2014.